Bioethics of Genetic Testing for Hereditary Breast Cancer

Hereditary Breast Cancer

Volumn , Issue , 2007, Pages 35-52

  Peshkin, Beth N ^a   Burke, Wylie ^b  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938689363     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420020366-7     Document Type: Chapter

References (92)

1. Myriad Genetics 2006 Annual Report. Available at: www.myriad.com/downloads/MYGN_AR2006.pdf (accessed June 2007).
2. Beauchamp TL, Childress JF. Principles of Biomedical Ethics. 5th ed. Oxford: Oxford University Press, 2000.
3. Burke W, Press N. Ethical obligations and counseling challenges in cancer genetics. J Natl Compr Canc Netw 2006; 4(2):185-191.
4. Burke W, Press N. Genetics as a tool to improve cancer outcomes: ethics and policy. Nat Rev Cancer 2006; 6(6):476-482.
5. Offit K. Psychological, ethical, and legal issues in cancer risk counseling. In: Offit K, ed. Clinical Cancer Genetics: Risk Counseling and Management. New York: Wiley-Liss, 1998: 287-316.
6. Halbert CH, Kessler LJ, Mitchell E. Genetic testing for inherited breast cancer risk in African Americans. Cancer Invest 2005; 23(4):285-295.
7. Oloparde OI. Genetics in clinical cancer care: a promise unfulfilled among minority populations. Cancer Epidemiol Biomarkers Prev 2004; 13(11 Pt 1):1683-1686.
8. Jonsen AR, Siegler M, Winslade WJ. Clinical Ethics: A Practical Approach to Ethical Decisions in Clinical Medicine. 5th ed. New York: McGraw-Hill, 2002.
9. The American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure, ASHG Statement. Professional disclosure of familial genetic information. Am J Hum Genet 1998; 62(2):474-483.
10. American Society of Clinical Oncology. Policy statement of the American Society of Clinical Oncology Update: genetic testing for cancer susceptibility. J Clin Oncol 2003; 21(12): 2397-2406.
11. Hampel H, Sweet K, Westman JA, et al. Referral for cancer genetics consultation: a review and compilation of risk assessment criteria. J Med Genet 2004; 41(2):81-91.
12. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast and ovarian. Clin Pract Guidelines Oncol 2007; 1:1-30. Available at: http://www.nccn.org/professionals/physician_gls/PDF/genetics_screening.pdf (accessed June 2007).
13. U.S. Preventive Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005; 143(5):355-361. Erratum in: Ann Intern Med 2005; 143(7):547.
14. GeneTests: Medical Genetics Information Resource (database online). Copyright, University of Washington, Seattle. 1993-2007. Available at: http://www.genetests.org (accessed June 2007).
15. Offit K, Garber J, Grady M, et al. ASCO Curriculum: Cancer Genetics and Cancer Predisposition Testing. 2nd ed. Alexandria, VA: ASCO Publishing, 2004.
16. McKinnon WC, Baty BJ, Bennett RL, et al. Predisposition genetic testing for late-onset disorders in adults. A position paper of the National Society of Genetic Counselors. JAMA 1997; 278(15):1217-1220.
17. Trepanier A, Ahrens M, McKinnon W, et al. Genetic cancer risk assessment and counseling: recommendations of the national society of genetic counselors. J Genet Couns 2004; 13(2): 83-114.
18. Andrews L, Meiser B, Apicella C, et al. Psychological impact of genetic testing for breast cancer susceptibility in women of Ashkenazi Jewish background: a prospective study. Genet Test 2004; 8(3):240-247.
19. Bluman LG, Rimer BK, Berry DA, et al. Attitudes, knowledge, and risk perceptions of women with breast and/or ovarian cancer considering testing for BRCA1 and BRCA2. J Clin Oncol 1999; 17(3):1040-1046.
20. Braithwaite D, Emery J, Walter F, et al. Psychological impact of genetic counseling for familial cancer: a systematic review and met-analysis. J Natl Cancer Inst 2004; 96(2): 122-133.
21. Grosfeld FJM, Lips CJM, Beemer FA, et al. Who is at risk for psychological distress in genetic testing programs for hereditary cancer disorders? J Genet Couns 2000; 9(3):253-266.
22. Geller G, Botkin JR, Green MJ, et al. Genetic testing for susceptibility to adult-onset cancer. The process and content of informed consent. JAMA 1997; 277(18):1467-1474.
23. Cull A, Miller H, Porterfield T, et al. The use of videotaped information in cancer genetic counselling: a randomized evaluation study. Br J Cancer 1998; 77(5):830-837.
24. Green MJ, Peterson SK, Baker MW, et al. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA 2004; 292(4):442-452.
25. Skinner CS, Schildkraut JM, Berry D, et al. Pre-counseling education materials for BRCA testing: does tailoring make a difference? Genet Test 2002; 6(2):93-105.
26. Culver JO, Hull JL, Dunne DF, et al. Oncologists’ opinions on genetic testing for breast and ovarian cancer. Genet Med 2001; 3(2):120-125.
27. Pichert G, Dietrich D, Moosmann P, et al. Swiss primary care physicians’ knowledge, attitudes and perception towards genetic testing for hereditary breast cancer. Fam Cancer 2003; 2(3-4):153-158.
28. Reutenauer JE. Medical malpractice liability in the era of genetic susceptibility testing. Quinnipiac Law Rev 2000; 19:539.
29. Severin JM. Genetic susceptibility for specific cancers: medical liability for the clinician. Cancer 1999; 86(8):1744-1749.
30. Wideroff L, Vadaparampil ST, Greene MH, et al. Hereditary breast/ovarian and colorectal cancer genetics knowledge in a national sample of US physicians. J Med Genet 2005; 42(10): 749-755.
31. Helmes AW, Culver JO, Bowen DJ. Results of a randomized study of telephone versus in-person breast cancer risk counseling. Patient Educ Couns 2006; 64(1-3):96-103.
32. Wolfberg AJ. Genes on the web-direct-to-consumer marketing of genetic testing. N Engl J Med 2006; 355(6):543-545.
33. Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004; 22(10):1823-1829.
34. Tinley ST, Houfek J, Watson P, et al. Screening adherence in BRCA1/2 families is associated with primary physicians’ behavior. Am J Med Genet A 2004; 125(1):5-11.
35. Hunter AGW, Sharpe N, Mullen M, et al. Ethical, legal, and practical concerns about recontacting patients to inform them of new information: the case in medical genetics. Am J Med Genet 2001; 103(4):265-276.
36. National Partnership for Women and Families on behalf of the Coalition for Genetic Fairness. Faces of Genetic Discrimination: How Genetic Discrimination Affects Real People. July 2004. Available at: http://www.geneticalliance.org/ksc_assets/documents/facesofgeneticdiscrimination. pdf (Accessed June 2007).
37. Kass NE, Hull SC, Natowicz MR, et al. Medical privacy and the disclosure of personal medical information: the beliefs and experiences of those with genetic and other clinical conditions. Am J Med Genet A 2004; 128(3):261-270.
38. Lapham EV, Kozma C, Weiss JO. Genetic discrimination: perspectives of consumers. Science 1996; 274(5287):621-624.
39. Otlowski MF, Taylor SD, Barlow-Stewart KK. Genetic discrimination: too few data. Eur J Hum Genet 2003; 11(1):1-2.
40. Apse KA, Biesecker BB, Giardiello FM, et al. Perceptions of genetic discrimination among at-risk relatives of colorectal cancer patients. Genet Med 2004; 6(6):510-516.
41. Armstrong KA, Calzone K, Stopfer J, et al. Factors associated with decisions about clinical BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 2000; 9(11):1251-1254.
42. Health Insurance Portability and Accountability Act 42 USC Sec 300gg-300gg-2, 1996.
43. Hustead JL, Goldman J. Genetics and privacy. Am J Law Med 2002; 28(2-3):285-307.
44. Americans with Disabilities Act. 42 USC Sec 12101-12213, 1990.
45. National Human Genome Research Institute. Legislation on Genetic Discrimination. http://genome.gov/10002077#2 (accessed September 2006).
46. Earley CL, Strong LC. Certificates of confidentiality: a valuable tool for protecting genetic data. Am J Hum Genet 1995; 57(3):727-731.
47. Godard B, Raeburn S, Pembrey M, et al. Genetic information and testing in insurance and employment: technical, social and ethical issues. Eur J Hum Genet 2003; 11(suppl 2): S123-S142.
48. Armstrong K, Weber B, FitzGerald G, et al. Life insurance and breast cancer risk assessment: adverse selection, genetic testing decisions, and discrimination. Am J Med Genet A 2003; 120 (3):359-364.
49. Smith KR, Zick CD, Mayer RN, et al. Voluntary disclosure of BRCA1 mutation test results. Genet Test 2002; 6(2):89-92.
50. Willner J. Hadassah opposes genetic test discrimination. Washington Jewish Week 1997 March 6:1.
51. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997; 336(20): 1401-1408.
52. Myriad Genetic Laboratories. Informed Consent for Hereditary Cancer Genetic Testing. Available at: http://www.myriadtests.com/doc/Myriad_Informed_Consent_Form.pdf (accessed October 2006).
53. Durfy SJ, Buchanan TE, Burke W. Testing for inherited susceptibility to breast cancer: a survey of informed consent forms for BRCA1 and BRCA2 mutation testing. Am J Med Genet 1998; 75(1):82-87.
54. Hamvas A, Madden KK, Nogee LM, et al. Informed consent for genetic research. Arch Pediatr Adolesc Med 2004; 158(6):551-555.
55. Lerman C, Narod S, Schulman K, et al. BRCA1 testing in families with hereditary breastovarian cancer. A prospective study of patient decision making and outcomes. JAMA 1996; 275(24):1885-1892.
56. Dugan RB, Wiesner GL, Juengst ET, et al. Duty to warn at-risk relatives for genetic disease: genetic counselors’ clinical experience. Am J Med Genet C Semin Med Genet 2003; 119(1): 27-34.
57. Falk JM, Dugan RB, O’Riordan MA, et al. Medical geneticists’ duty to warn at-risk relatives for genetic disease. Am J Med Genet A 2003; 120(3):374-380.
58. Hughes C, Lerman C, Schwartz M, et al. All in the family: evaluation of the process and content of sisters’ communication about BRCA1 and BRCA2 genetic test results. Am J Med Genet 2002; 107(2):143-150.
59. Julian-Reynier C, Eisinger F, Chabal F, et al. Disclosure to the family of breast/ovarian cancer genetic test results: patient’s willingness and associated factors. Am J Med Genet 2000; 94(1): 13-18.
60. McGivern R, Everett J, Yager GG, et al. Family communication about positive BRCA1 and BRCA2 genetic test results. Genet Med 2004; 6(6):503-509.
61. Wilson BJ, Forrest K, van Teijlingen ER, et al. Family communication about genetic risk: the little that is known. Community Genet 2004; 7(1):15-24.
62. Offit K, Groeger E, Turner S, et al. The “duty to warn” a patient’s family members about hereditary disease risk. JAMA 2004; 292(12):1469-1473.
63. United States Code of Federal Regulations, Title 45 x 164.512. Available at: http://a257.g. akamaitech.net/7/257/2422/13nov20061500/edocket.access.gpo.gov/cfr_2006/octqtr/pdf/45cfr164.512.pdf (accessed June 2007).
64. Tarasoff v the Regents of the University of California, 551 P 2d 334 (Cal 1976).
65. Pate v Threlkel, 661 So 2d 278 (Fla 1995).
66. Safer v Estate of Pack, 677 A2d 1188 (NJ App), appeal denied, 683 A2d 1163 (NJ 1996).
67. Godard B, Hurlimann, Letendre M, et al. Guidelines for disclosing genetic information to family members: from development to use. Fam Cancer 2006; 5(1):103-116.
68. American Medical Association. Code of Medical Ethics: Opinion E-2.131: Disclosure of Familial Risk in Genetic Testing. Available at: http://www.ama-assn.org/ama/pub/category/print/11963.html (accessed July 2006).
69. Peshkin BN, Isaacs C. Evaluation and management of women with BRCA1/2 mutations. Oncology (Williston Park) 2005; 19(11):1451-1459.
70. Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72(5):1117-1130. Erratum in: Am J Hum Genet 2003; 73(3):709.
71. Costalas Wagner J, Itzen M, Malick J, et al. Communication of BRCA1 and BRCA2 results to at-risk relatives: a cancer risk assessment program’s experience. Am J Med Genet C Semin Med Genet 2003; 119(1):11-18.
72. Loud JT, Weissman NE, Peters JA, et al. Deliberate deceit of family members: a challenge to providers of clinical genetics services. J Clin Oncol 2006; 24(10):1643-1646.
73. Doukas DJ, Berg JW. The family covenant and genetic testing. Am J Bioeth 2001; 1(3): 3-10.
74. Stock G. The family covenant: a flawed response to the dilemmas of genetic testing. Am J Bioeth 2001; 1(3):17-18.
75. Lynch HT. Family information service and hereditary cancer. Cancer 2001; 91(4):625-628.
76. Daly MB, Barsevick A, Miller SM, et al. Communicating genetic test results to the family: a six-step skills-building strategy. Fam Community Health 2001; 24(3):13-26.
77. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. Am J Hum Genet 1995; 57(5):1233-1241.
78. Nelson RM, Botkin JR, Kodish ED, et al. Ethical issues with genetic testing in pediatrics. Pediatrics 2001; 107(6):1451-1455.
79. Strahm B, Malkin D. Hereditary cancer predisposition in children: genetic basis and clinical implications. Int J Cancer 2006; 119(9):2001-2006.
80. Collins F. Commentary on the ASCO statement on genetic testing for cancer susceptibility. J Clin Oncol 1996; 14(5):1738-1740.
81. Tercyak KP, Peshkin BN, DeMarco TA, et al. Parent-child factors and their effect on communicating BRCA1/2 test results to children. Patient Educ Couns 2002; 47(2):145-153.
82. Campbell E, Ross LF. Professional and personal attitudes about access and confidentiality in the genetic testing of children: a pilot study. Genet Testing 2003; 7(2):123-130.
83. Campbell E, Ross LF. Parental attitudes and beliefs regarding the genetic testing in children. Community Genet 2005; 8(2):94-102.
84. Hamann HA, Croyle RT, Venne VL, et al. Attitudes toward the genetic testing of children among adults in a Utah-based kindred tested for a BRCA1 mutation. Am J Med Genet 2000; 92(1):25-32.
85. Duncan RE, Delatycki MB. Predictive testing in young people for adult-onset conditions: where is the empirical evidence? Clin Genet 2006; 69(1):8-16.
86. Elger BS, Harding TW. Testing adolescents for a hereditary breast cancer gene (BRCA1). Respecting their autonomy is in their best interest. Arch Pediatr Adolesc Med 2000; 154(2): 113-119.
87. Sharpe NF, Carter RF. Susceptibility testing. In: Sharpe NF, Carter RF, eds. Genetic Testing: Care, Consent, and Liability. New Jersey: John Wiley & Sons, Inc., 2006:268-291.
88. McConkie-Rosell A, Spiridigliozzi GA. “Family matters”: a conceptual framework for genetic testing in children. J Genet Couns 2004; 13(10):9-29.
89. Simpson JL, Carson SA, Cisneros P. Preimplantation genetic diagnosis (PGD) for heritable neoplasia. J Natl Cancer Inst Monogr 2005; 34:87-90.
90. Offit K, Kohut K, Clagett B, et al. Cancer genetic testing and assisted reproduction. J Clin Oncol 2006; 24(29):4775-4782.
91. Dyer C. HFEA widens its criteria for preimplantation diagnosis. BMJ 2006; 332(7551):1174.
92. Offit K, Levran O, Mullaney B, et al. Shared genetic susceptibility to breast cancer, brain tumors, and Fanconi anemia. J Natl Cancer Inst 2003; 95(20):1548-1551.